Although EGFR-TKIs are promising therapeutics for EGFR mutation-positive patients, it should be carefully administered to patients with accompanying COPD, pneumonitis, and pneumonia, and enrichment of inflammatory cytokines. Here, EGFR is linked to susceptibility to pneumonia measurement.